bes has been researched along with everolimus in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cha, KS; Chae, IH; Choi, YJ; Hong, BK; Kang, SH; Kang, WC; Kim, MK; Kim, SH; Kwun, JS; Lee, JH; Lee, SH; Park, JJ; Rha, SW; Suh, JW; Yoon, CH; Youn, TJ | 1 |
| Abe, M; Akasaka, T; Hanaoka, KI; Ikari, Y; Ishihara, T; Ishikawa, T; Kadota, K; Katoh, H; Kimura, T; Kozuma, K; Morimoto, T; Morino, Y; Muramatsu, T; Nakagawa, Y; Natsuaki, M; Nishikawa, H; Okada, K; Ono, K; Tamura, T; Tanabe, K; Taniguchi, R; Watanabe, H; Yamamoto, K | 1 |
2 trial(s) available for bes and everolimus
| Article | Year |
|---|---|
BioMatrix Versus Orsiro Stents for Coronary Artery Disease: A Multicenter, Randomized, Open-Label Study.
Topics: Absorbable Implants; Coronary Artery Disease; Drug-Eluting Stents; Everolimus; Humans; Percutaneous Coronary Intervention; Polymers; Prospective Studies; Prosthesis Design; Sirolimus; Treatment Outcome | 2023 |
Biodegradable or durable polymer drug-eluting stents in patients with coronary artery disease: ten-year outcomes of the randomised NEXT Trial.
Topics: Absorbable Implants; Coronary Artery Disease; Drug-Eluting Stents; Everolimus; Follow-Up Studies; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Polymers; Sirolimus; Treatment Outcome | 2023 |